Hemoglobinopathies Market Size, Share & Trends Report

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: 978-1-68038-736-0
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Market Segmentation
                      1.1.1 Estimates and Forecast Timeline
                 1.2 Research Methodology
                 1.3 Information Procurement
                      1.3.1 Purchased Database
                      1.3.2 GVR’s Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                      1.3.5 Details of Primary Research
                 1.4 Information or Data Analysis
                      1.4.1 Data Analysis Models
                 1.5 Market Formulation & Validation
                 1.6 Model Details
                      1.6.1 Commodity Flow Analysis
                           1.6.1.1 Approach 1: Commodity Flow Approach
                           1.6.1.2 Approach 2: Country-wise Market Estimation Using Bottom-Up Approach
                 1.7 Global Market: CAGR Calculation
                 1.8 Research Assumptions
                 1.9 List of Secondary Sources
                 1.10 Objectives
                      1.10.1 Objective 1:
                      1.10.2 Objective 2:
                 1.11 List of Abbreviations
Chapter 2 Executive Summary
                 2.1 Market Summary
Chapter 3 Global Hemoglobinopathies Market Variables, Trends & Scope
                 3.1 Penetration and Growth Prospect Mapping
                 3.2 Epidemiology Assessment of Hemoglobinopathies
                      3.2.1 Sickle cell disease
                      3.2.2 Thalassemia
                 3.3 Market Variable Analysis
                      3.3.1 Increasing prevalence of hemoglobinopathies in under-developed countries
                      3.3.2 High unmet needs
                      3.3.3 Increasing R&D investment
                      3.3.4 Initiatives to improve disease awareness levels
                 3.4 Market Restraint Analysis
                      3.4.1 Lack of healthcare infrastructure
                      3.4.2 High cost of treatment
                 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
                 3.6 Porter’s Five Forces Analysis
Chapter 4 Hemoglobinopathies Market - Segment Analysis, by Type, 2017 - 2028 (USD Million)
                 4.1 Market: Type Movement Analysis
                 4.2 Thalassemia
                      4.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
                      4.2.2 Alpha Thalassemia
                      4.2.3 Beta thalassemia
                 4.3 Sickle Cell Disease
                      4.3.1 Market estimates and forecast, 2017 - 2028 (USD Million)
                 4.4 Other Hemoglobin (Hb) Variants
                      4.4.1 Market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 5 Hemoglobinopathies Market - Segment Analysis, by Diagnosis, 2017 - 2028 (USD Million)
                 5.1 Hemoglobinopathies Market: Diagnosis Movement Analysis
                 5.2 Thalassemia Diagnosis
                      5.2.1 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
                      5.2.2 Blood Test
                      5.2.3 Genetic Test
                      5.2.4 Prenatal Genetic Test
                      5.2.5 Pre-implantation Genetic Diagnosis
                      5.2.6 Electrophoresis
                      5.2.7 Others
                 5.3 Sickle Cell Disease Diagnosis
                      5.3.1 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
                      5.3.2 Blood Test
                      5.3.3 Genetic Test
                      5.3.4 Prenatal Genetic Test
                      5.3.5 Electrophoresis
                      5.3.6 Others
                 5.4 Other Hemoglobin (Hb) Variants Diagnosis
                      5.4.1 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
                      5.4.2 Blood Test
                      5.4.3 Genetic Test
                      5.4.4 Prenatal Genetic Test
                      5.4.5 Electrophoresis
                      5.4.6 Others
Chapter 6 Hemoglobinopathies Market - Segment Analysis, by Therapy, 2017 - 2028 (USD Million)
                 6.1 Hemoglobinopathies Market: Therapy Movement Analysis
                 6.2 Thalassemia Therapy
                      6.2.1 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
                      6.2.2 Blood Transfusion
                      6.2.3 Iron Chelation Therapy
                      6.2.4 Bone Marrow Transplant
                      6.2.5 Others
                 6.3 Sickle Cell Disease Therapy
                      6.3.1 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
                      6.3.2 Blood Transfusion
                      6.3.3 Hydroxyurea
                      6.3.4 Bone Marrow Transplant
                      6.3.5 Others
                 6.4 Other Hemoglobin (Hb) Variants Therapy
                      6.4.1 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
                      6.4.2 Blood Transfusion
                      6.4.3 Hydroxyurea
                      6.4.4 Iron Chelation Therapy
                      6.4.5 Bone Marrow Transplant
                      6.4.6 Others
Chapter 7 Hemoglobinopathies Market - Segment Analysis, by Region, 2017 - 2028 (USD Million)
                 7.1 Hemoglobinopathies Market: Regional Movement Analysis
                 7.2 North America
                      7.2.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
                      7.2.2 U.S.
                           7.2.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
                 7.3 Canada
                           7.3.1.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
                 7.4 Europe
                      7.4.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.2 U.K.
                           7.4.2.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.3 Germany
                           7.4.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.4 France
                           7.4.4.1 France market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.5 Italy
                           7.4.5.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.6 Spain
                           7.4.6.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
                      7.4.7 Russia
                           7.4.7.1 Russia market estimates and forecast, 2017 - 2028 (USD Million)
                 7.5 Asia Pacific
                      7.5.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.2 Japan
                           7.5.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.3 China
                           7.5.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.4 India
                           7.5.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.5 South Korea
                           7.5.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.6 Singapore
                           7.5.6.1 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
                      7.5.7 Australia
                           7.5.7.1 Australia market estimates and forecast, 2017 - 2028 (USD Million)
                 7.6 Latin America
                      7.6.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
                      7.6.2 Brazil
                           7.6.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
                      7.6.3 Mexico
                           7.6.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
                      7.6.4 Argentina
                           7.6.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
                 7.7 Middle East & Africa
                      7.7.1 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
                      7.7.2 South Africa
                           7.7.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
                      7.7.3 United Arab Emirates
                           7.7.3.1 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
                      7.7.4 Saudi Arabia
                           7.7.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 8 Competitive Analysis
                 8.1 Recent Developments & Impact Analysis, by Key Market Participants
                      8.1.1 Ansoff matrix
                      8.1.2 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
                      8.1.3 Innovators
                      8.1.4 Market Leaders
                 8.2 Vendor Landscape
                      8.2.1 List of key distributors and channel partners
                      8.2.2 Key customers
                      8.2.3 Strategic framework
                 8.3 Major Deals and Strategic Alliances Analysis
                           8.3.1.1 New product launch
                           8.3.1.2 Mergers and acquisitions
                           8.3.1.3 Expansion
                           8.3.1.4 Partnerships
                           8.3.1.5 Marketing & promotions
                 8.4 Company Profiles
                      8.4.1 Sangamo Therapeutics
                           8.4.1.1 Company overview
                           8.4.1.2 Financial performance
                           8.4.1.3 Product benchmarking
                           8.4.1.4 Strategic initiatives
                      8.4.2 bluebird bio, Inc.
                           8.4.2.1 Company overview
                           8.4.2.2 Financial performance
                           8.4.2.3 Product benchmarking
                           8.4.2.4 Strategic initiatives
                      8.4.3 Global Blood Therapeutics, Inc.
                           8.4.3.1 Company overview
                           8.4.3.2 Financial performance
                           8.4.3.3 Product benchmarking
                           8.4.3.4 Strategic initiatives
                      8.4.4 Pfizer, Inc.
                           8.4.4.1 Company overview
                           8.4.4.2 Financial performance
                           8.4.4.3 Product benchmarking
                           8.4.4.4 Strategic initiatives
                      8.4.5 Emmaus Life Sciences, Inc.
                           8.4.5.1 Company overview
                           8.4.5.2 Financial performance
                           8.4.5.3 Product benchmarking
                           8.4.5.4 Strategic initiatives
                      8.4.6 Prolong Pharmaceuticals, LLC
                           8.4.6.1 Company overview
                           8.4.6.2 Product benchmarking
                           8.4.6.3 Strategic initiatives
                      8.4.7 Celgene Corporation (BMS)
                           8.4.7.1 Company overview
                           8.4.7.2 Financial performance
                           8.4.7.3 Product benchmarking
                           8.4.7.4 Strategic initiatives
                      8.4.8 Bioverativ Inc. (Sanofi)
                           8.4.8.1 Company overview
                           8.4.8.3 Product benchmarking
                           8.4.8.4 Strategic initiatives
                      8.4.9 Gamida Cell
                           8.4.9.1 Company overview
                           8.4.9.2 Financial performance
                           8.4.9.3 Product benchmarking
                           8.4.9.4 Strategic initiatives
                      8.4.10 Novartis AG
                           8.4.10.1 Company overview
                           8.4.10.2 Financial Performance
                           8.4.10.3 Product Benchmarking
                           8.4.10.4 Strategic initiatives


List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Descriptive Analysis of the Age at Diagnosis Laboratory Evaluation of Hbs, Hbf, and Hemolytic State and Complications Recorded
Table 4 List Of Normal Human Hemoglobin
Table 5 Hemoglobinopathies Market: Product Pipeline
Table 6 Leading Market Players Anticipated to Witness Highest Growth
Table 12 North America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 13 North America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 14 North America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 14 North America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 15 U.S. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 16 U.S. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 16 U.S. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 17 Canada Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 18 Canada Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 18 Canada Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 19 Europe Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 20 Europe Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 21 Europe Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 21 Europe Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 22 U.K. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 23 U.K. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 23 U.K. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 24 Germany Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 25 Germany Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 25 Germany Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 26 France Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 27 France Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 27 France Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 28 Spain Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 29 Spain Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 29 Spain Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 30 Italy Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 31 Italy Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 31 Italy Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 30 Russia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 31 Russia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 31 Russia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 32 Asia Pacific Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 33 Asia Pacific Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 34 Asia Pacific Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 34 Asia Pacific Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 35 Japan Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 36 Japan Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
Table 36 Japan Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
Table 37 China Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 38 China Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 38 China Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 39 India Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 40 India Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 40 India Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 41 South Korea Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 42 South Korea Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 43 South Korea Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 41 Singapore Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 42 Singapore Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 43 Singapore Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 41 Australia Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
Table 42 Australia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 43 Australia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 44 Latin America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 45 Latin America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 46 Latin America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 46 Latin America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 47 Brazil Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 48 Brazil Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
Table 48 Brazil Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
Table 49 Mexico Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 50 Mexico Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 50 Mexico Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 51 Argentina Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 52 Argentina Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 52 Argentina Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 53 Middle East & Africa Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
Table 54 Middle East & Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 55 Middle East & Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 55 Middle East & Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 56 South Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 57 South Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 57 South Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 58 Saudi Arabia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 59 Saudi Arabia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 59 Saudi Arabia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
Table 60 United Arab Emirates Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
Table 61 United Arab Emirates Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
Table 61 United Arab Emirates Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)


List of Figures

Fig. 1 Hemoglobinopathies market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Hemoglobinopathies market snapshot
Fig. 10 Penetration and growth prospect mapping
Fig. 11 Hemoglobinopathies market driver impact
Fig. 12 Prevalence of hemoglobinopathies gene carriers
Fig. 13 Hemoglobinopathies market restraint impact
Fig. 14 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 15 Porter’s five forces analysis
Fig. 16 Hemoglobinopathies market: Type outlook and key takeaways
Fig. 17 Hemoglobinopathies market: Type movement analysis
Fig. 18 Thalassemia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 19 Sickle cell disease market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 20 Other hemoglobin (Hb) variants market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 21 Hemoglobinopathies market: Diagnosis outlook and key takeaways
Fig. 22 Hemoglobinopathies market: Diagnosis movement analysis
Fig. 23 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 24 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 25 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 26 Hemoglobinopathies market: Therapy outlook and key takeaways
Fig. 27 Hemoglobinopathies market: Therapy movement analysis
Fig. 28 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 29 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 30 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 31 Hemoglobinopathies market: Regional outlook and key takeaways
Fig. 32 Hemoglobinopathies market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 U.K.
Fig. 42 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 France
Fig. 46 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 Spain
Fig. 50 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 Russia
Fig. 52 Russia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 53 Asia Pacific
Fig. 54 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 Japan
Fig. 56 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 China
Fig. 58 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 India
Fig. 60 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 South Korea
Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 Singapore
Fig. 64 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 65 Australia
Fig. 66 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 Latin America
Fig. 68 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Brazil
Fig. 70 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 71 Mexico
Fig. 72 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 73 Argentina
Fig. 74 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 75 Middle East & Africa
Fig. 76 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 77 South Africa
Fig. 78 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 79 United Arab Emirates
Fig. 80 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 81 Saudi Arabia
Fig. 82 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 83 Ansoff Matrix
Fig. 84 Competition categorization
Fig. 85 Strategic framework
Fig. 86 Strategy mapping

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon